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Volume 6Available online 30 April 2021Background: Studies evaluating the effects of the COVID-19 pandemic on public healthcare systems are limited,
particularly in cancer management. As no such studies have been carried out in Spain, our objective is to describe
and quantify the impact of the COVID-19 pandemic on cancer patients in Spanish hospitals during the first wave of
the pandemic.
Materials and methods: This retrospective, multicenter, nationwide study collected information from hospital
departments treating oncology patients. An electronic questionnaire comparing outcomes and management of
oncohematological patients for the March-June 2019 and March-June 2020 periods was used.
Results: Information from 78 departments (36 tertiary hospitals) was analyzed. Forty-four departments implemented
adapted protocols during March 2020. Most of these (n ¼ 38/44; 86.4%) carried out COVID-19 triage, while 26 of
44 (59.1%) carried out onsite polymerase chain reaction tests for clinically suspected cases. A shift from in-person
to telephone visits was observed in 43 of 44 (97.7%) departments. Comparing the March-June 2019 and March-
June 2020 periods, the number of new patients decreased by 20.8% (from 160.2 to 126.4). Decreases were also
seen in the mean number of total (2858.2 versus 1686.1) and cancer (465.5 versus 367.2) biopsies, as well as the
mean number of bone marrow biopsies (30.5 versus 18.6). Concerning the number of patients visiting specific
cancer care departments, a decrease from 2019 to 2020 was seen for mean number of chemotherapy treatments
(712.7 versus 643.8) and radiation therapy (2169.9 versus 2139.9). Finally, a reduction from 2019 to 2020 of 12.9%
(from 8.6 to 7.4) in the mean number of patients included in clinical trials was noted.
Conclusions: This study provides the first comprehensive data concerning the impact of COVID-19 on cancer care in
Spain. The pandemic caused a 20.8% decrease in newly diagnosed patients, which may impact future outcomes.
Measures must be taken to ensure cancer management receives priority in times of healthcare emergencies.
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Coronaviruses are one group of the most pathogenic agents
affecting the human respiratory system.1 Coronavirus out-
breakswere responsible forhealthcareemergencies suchas the
severe acute respiratory syndrome (SARS)-CoV reported in
2003, and theMiddle East respiratory syndrome (MERS)-CoV in
2012.2 In December 2019, a new coronavirus disease (COVID-
19) emerging most likely from China has been responsible forondence to: Dr MariLuz Amador, Medical Director, Spanish Associa-
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- Issue 3 - 2021causing an atypical form of pneumonia.3,4 Since then, the
etiological agent, named SARS-CoV-2, has spread worldwide,
with the World Health Organization declaring the current
outbreak a public health emergency on 30 January 2020.5 In
Spain, the first case of COVID-19 was reported on 31 January
2020.6 Between 1 March and 30 June 2020, a total of 240 978
individuals tested positive for COVID-19 in Spain and 27 134
deaths were reported.7 The disease exhibits a wide variety of
clinical manifestations ranging from asymptomatic or mild
forms to severe pneumonia with respiratory and systemic,
multi-organ dysfunction (including acute respiratory distress
syndrome, sepsis, and septic shock) requiring intensive care
treatment.1,8 As a consequence of the COVID-19 pandemic,
routine clinical practices in Spain were modified extensively to
deal with such a critical healthcare scenario.9https://doi.org/10.1016/j.esmoop.2021.100157 1
ESMO Open M. Amador et al.Cancer is a major public health issue worldwide10 and the
second most common cause of mortality, accounting for
approximately one in six deaths. By 2030 its incidence is
expected to increase by w45%,10 making it the world’s
leading cause of death. As cancer morbidity and mortality
are directly related to the stage at diagnosis,11 earlier
detection and treatment are therefore associated with
better prognosis and survival outcomes.12,13 Cancer pa-
tients are a particularly at-risk population for developing
severe COVID-19. This is particularly the case for patients
receiving active treatment, those who have metastatic dis-
ease, and those who are affected by lung and hematological
malignancies.14-17
Given the impact of COVID-19 on healthcare resources,
the redeployment of physicians (including oncologists) to
COVID-19-specific tasks, and the possible reluctance of sick
people to seek medical assistance at healthcare facilities,
there is a heightened risk that the diagnosis and treatment
of cancer patients during the pandemic will be delayed for
unacceptably long periods. To this end, multicenter studies
evaluating the effect of the pandemic on public healthcare
systems are limited, particularly in relation to cancer man-
agement.18-21 As no such studies have been carried out in
Spain, the objective of the present work was to evaluate
and quantify the impact of the COVID-19 pandemic on the
hospital-based care of cancer patients during the first wave
of the pandemic from March to June 2020 in Spain.
MATERIALS AND METHODS
Study design
This was a retrospective, multicenter, nationwide study in
which data were collected from participating hospitals
across four key departments involved in the management of
oncohematological patients (hematology, medical oncology,
radiation oncology, and pathology). Data were collected for
the March to June period of 2019 and compared with the
same period in 2020. Five national scientific societies in
Spain [Spanish Society of Pathological Anatomy (SEAP-IAP);
Spanish Society of Oncological Nursing (SEEO); Spanish So-
ciety of Hematology and Hemotherapy (SEHH); Spanish
Society of Medical Oncology (SEOM); and Spanish Society of
Radiation Oncology (SEOR)] together with the Spanish As-
sociation Against Cancer (AECC) collaborated in the study.
An electronic (e-)questionnaire addressing a range of vari-
ables was sent to departments as indicated above in 37
public general hospitals. The questionnaire for each
department is shown in Supplementary Appendix, available
at https://doi.org/10.1016/j.esmoop.2021.100157. All
participating sites were public general hospitals providing
tertiary level care, some of which were the only hospitals of
this type in the concerned region. As Spain has fewer than a
hundred public general tertiary care hospitals, the overall
obtained data are considered representative of the national
situation. The number of participating hospitals per region
was chosen to be indicative of the COVID-19 incidence rate
during the first wave, which was heterogeneous across the
country. This study was approved by the Ethics Review2 https://doi.org/10.1016/j.esmoop.2021.100157Board of the 12 de Octubre University Hospital in Madrid
(20/410, 28 July 2020).
Data collection and variables evaluated
The e-questionnaire was developed by physicians directly
involved in the hospital care of cancer patients during the
first wave of the pandemic in Spain (March to June 2020).
Data were retrospectively collected between 30 July and
12 October 2020 from the mentioned departments. The
questionnaire was composed of two main sections: (i) anti-
COVID-19-specific measures taken in relation to patient care
as measured by the implementation of specific action pro-
tocols and general measures taken in each department to
adapt to the situation; and (ii) impact on cancer care,
measuring changes in the number of new patient referrals,
number of diagnostic procedures (such as solid tumors and
bone marrow biopsies), number of treatments adminis-
tered, and finally participation in clinical trials. It should be
noted that between March and June 2020, polymerase
chain reaction (PCR) tests were only carried out on clinically
suspected cases. The e-questionnaire used to record re-
sponses to the different variables was sent to the heads of
the participating departments’ participants.
Data analysis
The impact of the pandemic was established by assessing
absolute and relative changes during the considered period
(March to June) in 2019 (control) versus the same period in
2020. Categorical variables were expressed as absolute and
relative frequencies, whereas continuous variables as the
mean and range (minimum and maximum values). All
descriptive analyses were carried out with the statistical
software package SAS 9.4 (SAS Institute, NC; 2013).22
RESULTS
Participating hospitals
A total of 37 tertiary hospitals were invited to participate in
the study (Figure 1), with 36 of the 37 (97.3%) sites
providing data from at least one of the four departments.
Overall, the participation of the departments was: hema-
tology, 12 hospitals (32%); medical oncology, 13 hospitals
(35%); radiation oncology: 19 hospitals (51%); and pathol-
ogy: 34 hospitals (92%). Information from a total of 78
departments was available for analysis. The complete list of
hospitals providing data from each department and the
names of participating researchers are shown in the
Supplementary Appendix, available at https://doi.org/10.
1016/j.esmoop.2021.100157.
Specific anti-COVID-19 measurements
Forty-four departments initiated specific action protocols
against COVID-19; 24 (54.5%) of these did so in the first half
of March 2020, and the remainder in the second half of that
same month (Table 1). Of the 44 departments, 38 (86.4%)
implemented COVID-19 infection and contact triage pro-
cedures during routine clinical practice, and 26 departmentsVolume 6 - Issue 3 - 2021
Figure 1. Distribution of participating hospitals in the autonomous regions of Spain and the number of COVID-19 cases treated by each.
The value in white indicates the number of participating hospitals in each region.
M. Amador et al. ESMO Open(59.1%) carried out onsite PCR tests for clinically suspected
COVID-19 cases. A shift from in-person to telephone/
internet consultations was observed in 43 (97.7%) of the 44
departments, while physical assistance was maintained in
95.5% of departments for those patients whose condition
could not be evaluated by telephone. Most departments
(97.7%, n ¼ 43/44) followed national guidelines (SEHH
guidelines for hematology; SEOM guidelines for medical
oncology; SEOR guidelines for radiation oncology) for the
modification of therapeutic strategies. Overall, between
March and June 2020, out of a mean of 34.3 patients
(range: 0-215) per department, 77.5% (mean 26.6, range: 0-
125) of patients who were clinically suspected of having
COVID-19 tested positive. Among symptomatic patients,Table 1. Specific anti-COVID-19 measurements





Date of first implemented measures
1-15 March 24 (54.5) 9 (75
16-30 March 20 (45.5) 3 (25
Separated circuits: non-contaminated/contaminated 38 (86.4) 12 (10
Onsite PCR 26 (59.1) 10 (83
Change from physical to telemedicine consultations 43 (97.7) 12 (10
Ongoing physical visits in cases where necessary 42 (95.5) 12 (10
Specific guidelines for the modification of therapeutic
strategies
From same department 35 (79.5) 10 (83
National guidelines 43 (97.7) 12 (10
International guidelines 34 (77.3) 8 (66
Other guidelines 12 (27.3) 4 (33
PCR, polymerase chain reaction.
Volume 6 - Issue 3 - 202162.1% (n ¼ 21.3, range: 0-159) were admitted to hospital,
and 19.7% (mean 6.8, range: 0-30) of them died thereafter.New and successive medical visits
Compared with the March-June period in 2019, the mean
number of new patient visits decreased by 20.8% (from
160.2, range: 151.4-173.1, to 126.4, range: 105.3-144.3) for
the same period in 2020. For successive consultations
(including follow-up, treatment, and other kinds of visit),
many were shifted from in-person to remote (telephone)
visits, with the mean number of telephone visits increasing
three-fold compared with the same period in 2019. On the
other hand, the mean number of physical visits decreasedology (n [ 12) Medical oncology (n [ 13)
n (%)
Radiation oncology (n [ 19)
n (%)
.0) 8 (61.5) 7 (36.8)
.0) 5 (38.5) 12 (63.2)
0.0) 13 (100.0) 13 (68.4)
.3) 9 (69.2) 7 (36.8)
0.0) 13 (100.0) 18 (94.7)
0.0) 13 (100.0) 17 (89.5)
.3) 10 (76.9) 15 (78.9)
0.0) 13 (100.0) 18 (94.7)
.7) 10 (76.9) 16 (84.2)
.3) 4 (30.8) 4 (21.1)
https://doi.org/10.1016/j.esmoop.2021.100157 3








New visits 20.8 160.2 versus 126.4
Successive consultations
Telephone 298.5 118.0 versus 467.3
Physical 22.3 1224.4 versus 952.0
Diagnosisb
Cytologies 57.1 1950.9 versus 843.7
Cytologies with cancer
diagnosis
30.2 57.7 versus 40.0
Ratio cancer/cytologies 52.2 4.1 versus 6.3
Biopsies 41.2 2858.2 versus 1686.1
Biopsies with cancer
diagnosis
21.2 465.5 versus 367.2
Ratio cancer/biopsies 40.9 16.6 versus 23.4
Specific diagnostic
proceduresc
Bone marrow aspirates 31.4 58.8 versus 39.9
Bone marrow biopsies 38.3 30.5 versus 18.6
Flow cytometry tests 12.5 220.7 versus 192.6
Neoplastic genetic
studies
15.8 626.0 versus 524.0
Treatments
Patients treated in day
hospitals (ambulatory
therapy)d
14.3 980.0 versus 837.9
Treatments in day
hospitalsd
7.7 1500.1 versus 1377.7
Patients treated with
chemotherapyd
9.5 712.7 versus 643.8
Patients treated with
G-CSFd








2.1 189.3 versus 191.6
Hematopoietic stem cell
transplantsf
Autologous 7.5 3.3 versus 2.9
Allogenic 27.2 3.4 versus 2.4
Radiation therapiesg
Patients treated 5.3 146.4 versus 138.4
Treatments carried out
(sessions)
1.3 2169.9 versus 2139.9
Clinical research activitiesh




due to the pandemic
2.2 e
Clinical trials recruitment 32.1 30.4 versus 40.1
Screening visits 1.6 14.6 versus 13.9
Enrolled patients 12.9 8.6 versus 7.4
G-CSF, granulocyte colony-stimulating factors.
a Data obtained from 37 departments (hematology, medical oncology, and radiation
oncology) of 28 hospitals.
b Pathology departments of 34 hospitals.
c Hematology departments of nine hospitals.
d Seven hematology and nine medical oncology departments.
e Medical oncology departments of eight hospitals.
f Hematology departments of six hospitals that carry out transplants.
g The radiation oncology departments of 18 hospitals.
h 29 departments (hematology, medical oncology, and radiation oncology) of 22
hospitals.
ESMO Open M. Amador et al.by 22.3% (from 1224.4, range: 1184.7-1282.6, to 952.0,
range: 758.6-1143.9) during the 2020 period compared
with 2019 (Table 2).4 https://doi.org/10.1016/j.esmoop.2021.100157Diagnostic procedures
For solid tumors, the mean number of total cytologies and
biopsies decreased by 57.1% (1950.9 versus 843.7) and
41.2% (2858.2 versus 1686.1), respectively, in the 2020
period compared with the 2019 period. Considering specific
cancer diagnoses, mean numbers were reduced by 30.2%
(57.7 versus 40.0) for cytologies and 21.2% (465.5 versus
367.2) for biopsies. Regarding diagnostic procedures carried
out on hematological patients in the 2020 period, a
decrease of 31.4% (58.8 versus 39.9) was reported for bone
marrow aspirates and 38.3% (30.5 versus 18.6) for bone
marrow biopsies compared with 2019 figures. The reduction
in the mean number of flow cytometry tests in 2020 versus
2019 was 12.5% (220.7 versus 192.6) and 15.8% (626.0
versus 524.0) for additional genetic studies on blood can-
cers (Table 2).Treatment delivery
We observed a decrease in 2020 of 14.3% in the mean
number of patients visiting day hospitals (980.0 versus
837.9), with a decrease of 9.5% in the mean number of
patients receiving chemotherapy (712.7 versus 643.8). The
use of granulocyte colony-stimulating factors increased by
27.0% in 2020 with respect to the same period in 2019 (64.0
versus 81.2). Interestingly, the use of immune checkpoint
inhibitors (ICIs) in 2020 increased by 11.0% compared with
2019 figures (121.4 versus 135.0). We also observed an in-
crease of 2.1% in the use of tyrosine kinase inhibitors (189.3
versus 191.6) in 2020 compared with 2019 data. The mean
number of autologous hematopoietic stem cell transplants
decreased by 7.5% (3.3 versus 2.9) in 2020 compared with
the same period in 2019, while the mean number of allo-
geneic transplants decreased by 27.2% (3.4 versus 2.4).
Finally, the mean number of patients visiting radiation
oncology facilities and the mean number of treatments
administered decreased by 5.3% (146.4 versus 138.4) and
1.3% (2169.9 versus 2139.9), respectively (Table 2).Clinical research
The inclusion of patients in oncology-specific clinical trials
decreased by 12.9% during the 2020 period compared with
the 2019 period (mean 7.4, range: 4.1-11.0, versus mean
8.6, range: 8.0-9.9), whereas an increase of 32.1% in the
2020 period compared with 2019 was observed in the
number of clinical trials in general (mean 40.1, range: 38.8-
41.7, versus mean 30.4, range: 28.7-31.5), presumably due
to COVID-19 research (Table 2).
DISCUSSION
The COVID-19 pandemic has dramatically impacted most
public healthcare systems around the world. The Spanish
public healthcare system guarantees universal health
coverage and free access for all Spanish individuals and
eligible foreigners.23 During the first wave of the COVID-19
pandemic (March to June 2020), the Spanish healthcare
system was forced to reorganize a large proportion of itsVolume 6 - Issue 3 - 2021
M. Amador et al. ESMO Openresources toward the management of SARS-CoV-2-infected
patients and to implement specific action protocols to
avoid the infection of healthy healthcare professionals and
patients admitted to or attending hospitals.24 The goal of
the present study was to collect, for the first time in Spain,
accurate data on the impact of the first wave of the
pandemic on care provision and outcomes in oncology pa-
tients from a representative sample of 36 hospitals.17,25,26
Our study presents some major limitations, such as its
retrospective nature and the exclusive hospital perspective
of cancer management as neither primary care nor
screening data were included (different sources for these
data exceeded our operational capacity). Additionally, not
all contacted departments responded to the questionnaire,
which may limit the representation since data could be
influenced by selection and measurement bias.
Our results reveal that routine practice in hematology,
medical oncology, radiation oncology, and pathology de-
partments in Spain was impacted early in the pandemic.
Specific action protocols were implemented during the
month of March 2020 in participating departments,
including the development of clinical triage protocols and
onsite COVID-19 PCR testing for patients attending hospi-
tals. These measurements aimed to protect all patients from
infection.
It is important to note that of all symptomatic patients,
62.1% were admitted, 77.5% were confirmed by PCR, and
19.7% died from COVID-19-related causes. It is also
important to point out that PCR testing was not routinely
available during the first wave of the pandemic in Spain
unless there was solid clinical evidence of suspected infec-
tion. This could explain the high rate of positive results in
tested patients. The 19.7% mortality rate for admitted
cancer patients was similar to that reported for the general
population who required hospital admission due to COVID-
19 at that time.27
We also observed a shift from physical visits to telephone
visits at most (97.7%) of the participating sites, particularly
for follow-up consultations. However, only a 14.3% decrease
was seen in the mean number of cancer patients being
cared for in day hospitals. In solid tumors, the shift from
intravenous to oral agents due to the pandemic situation
has been very limited (although no measurements on this
topic are available). For hematology malignancies, the
reduction in the number of day hospital treatments was
related to those therapies considered less relevant. How-
ever, others considered as more critical were less affected
(the number of therapies with ICIs increased). In-person
visits were also maintained for those cases where there
was a need for patients to be physically examined. Given
the above, it can be concluded that departments and
healthcare professionals assisting cancer patients reacted
early in the pandemic to protect their patients by imple-
menting specific measurements such as clinical triage or
PCR and by adapting practices to the given
circumstances.18,20,21
We observed similar trends to changing and adapting
care variables like successive visits to hospitals (includingVolume 6 - Issue 3 - 2021follow-up, review, and other visits that were not the first
visit to the specialist), with a three-fold increase in the
number of telephone visits and a 22.3% decrease of in-
person visits. Regarding treatments, we identified a
decrease of 9.5% in the mean number of chemotherapy
treatments and 1.3% in radiation treatments, together with
a clear increase in the use of colony-stimulating factors
(increase of 27.0% when compared with the same period in
2019) and ICIs (11.0%). All of these results corroborate the
effort made to adapt different treatment modalities and
schedules to the healthcare situation at the time. Differ-
ences between the decrease in systemic and radiation
treatments might reflect the use of radiotherapy as an
alternative to systemic and/or surgical treatment. In addi-
tion, data on other systemic treatments (chemotherapy,
ICIs, tyrosine kinase inhibitors) revealed similar efforts to
adapt to the prevailing situation while maintaining and
adapting treatments for patients with already diagnosed
solid tumors. That being said, the most concerning data for
us are those related to attention provided to newly diag-
nosed patients.18,20
For patients visiting an oncology or hematology depart-
ment for the first time, a decrease of 20.8% in the mean
number of new visits, considered as a surrogate of newly
diagnosed cases, was identified. Similarly, for solid tumors,
we observed a decrease (21.2%) in the mean number of
cancer biopsies carried out during the studied period. The
percentage differences between 2019 and 2020 with
respect to total cytologies and biopsies could indicate a
certain prioritization to perform these diagnostic proced-
ures when a cancer was suspected. For hematological tu-
mors, a decrease in the mean number of diagnostic
procedures such as bone marrow aspirates (31.4%) and
biopsies (38.3%) was reported, which likely reflects a
reduction in the number of consecutive explorations in
previously diagnosed patients (i.e. leukemia patients under
therapeutic monitoring), as well as a reduction of new di-
agnoses of diseases where bone marrow examination is
essential (myelodysplasia, leukemia, myeloma). In addition,
a reduction in the mean number of allogeneic (27.2%) and
autologous (7.5%) hematopoietic stem cell transplantations
was also noted, probably reflecting a delay in the per-
forming of these procedures as a strategy of physicians to
avoid deep and long-term myelosuppression in these
patients.
In our opinion, these data concerning the decrease in
new visits, cancer biopsies, and hematology diagnoses are
the most concerning of this study, but also potentially the
most actionable. While acknowledging the study’s limita-
tions, our data provide a good idea of the quantitative
impact of COVID-19 on cancer care and assistance. In
addition, our data are consistent with previously published
data from other countries,18,20,21 and individual institutions
in our country.28 A survey carried out by Cancer Research
UK showed that the pandemic impacted their testing (two
in five patients), cancer care (two in three patients), and
treatment (one in three patients).18 Dinmohamed et al.20
revealed a reduction in cancer diagnosis by 26% for allhttps://doi.org/10.1016/j.esmoop.2021.100157 5
ESMO Open M. Amador et al.cancer sites (excluding skin cancer) and 60% for skin cancer
(excluding basal cell carcinoma) in April 2020. Moreover,
Jazieh et al.21 reported a reduction of services in more than
half of all centers (55%) and the missing of at least one cycle
of therapy by >10% of cancer patients (46%). The situation
meant that patients were exposed to harm due to the
interruption of cancer-specific care (36% of centers) and
noncancer-related care (39%).
Our data highlight that one in five patients with cancer
was either not diagnosed or diagnosed late during the first
wave of the pandemic in Spain, where many (if not all) non-
COVID-19 diagnosis-related procedures were stopped. This
took place together with the collapse of Spain’s primary
healthcare system, which represents the most important
entry to the health system for cancer patients. Moreover,
and although this hypothesis cannot be quantified, we
consider that patients’ fear of being infected in hospitals
and primary care clinics might also have contributed to the
decrease of new cancer diagnoses. This ‘gap’ generated
during the first wave has probably not been covered to the
present time and might be even greater after the second
and third waves of the pandemic. These data are important
given their potential consequences, as it is well known that
an early diagnosis and treatment are associated with better
prognosis and survival outcomes in cancer patients.16,17
Delayed cancer treatment is related to increased mortality
across surgical, systemic treatment, and radiotherapy in-
dications.29 In this way, the delay in cancer diagnosis during
the COVID-19 pandemic will probably result in an increase
in the stage at which treatment is initiated for a large
proportion of patients and may impact long-term survival,
morbidity, and quality of life. Indeed, it has been estimated
that delays in cancer diagnosis will be responsible for an
additional 10 000 deaths from breast and colorectal cancer
in the coming 10 years in the USA.30 In a national
population-based modeling study in the UK, the impact on
net survival at 1, 3, and 5 years after diagnosis was used to
estimate the number of additional deaths that could be
attributed to cancer compared with pre-pandemic data.31
The increased rate of mortality due to breast, colorectal,
esophageal, and lung cancer could result in 3291-3621
additional deaths within 5 years.
Finally, the COVID-19 pandemic has also impacted clinical
research. In our study, the inclusion of patients in cancer
clinical trials was reduced by approximately 12.9%. The
American Society of Clinical Oncology (ASCO) recently
published recommendations for improving cancer research
and care during the COVID-19 pandemic.32 Among specific
goals, ASCO included the need to ‘recognize and address
threats to clinician, provider, and patient well-being; and
improve patient access to high-quality cancer care via tele-
medicine’. These recommendations are in agreement with
the results identified in our study.32 Without doubt, the
impact of COVID-19 on public healthcare systems in relation
to cancer is global, and this concern extends to other sectors
like the economy. This in turn may impact other issues
associated with cancer, such as research, which in Spain is
funded less than in some neighboring countries.21,31,33-366 https://doi.org/10.1016/j.esmoop.2021.100157Conclusions
This study provides the first comprehensive dataset
describing the negative impact of the COVID-19 pandemic
on cancer care in Spain. Oncology patients are particularly
vulnerable to this pandemic, presenting more frequent and
severe forms of disease, often requiring hospitalized care,
and with poorer evolution. In addition, we have docu-
mented a significant delay in cancer diagnosis and treat-
ment that may potentially have consequences on
outcomes: reduced survival time, less effective treatments,
and increased morbidity and suffering. We have shared
these results with Spain’s health authorities and suggest
cancer diagnosis and management should be prioritized in
critical times such as the current pandemic scenario. A
united approach is needed to address the shortfall in new
diagnoses created by this situation. Indeed, the solution is
likely to be complex and multidisciplinary (from evaluating
current structures and human resources to ensure that the
most vulnerable cancer patients are vaccinated in a timely
manner). At the time of writing, (February 2021), Spain was
experiencing a new wave of COVID-19, which in our
opinion, will increase delays in the diagnosis and treatment
of cancer patients if no concerted actions are taken, with
the impact no doubt to be felt heavily by patients and the
public healthcare system alike.
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